Objective: With the rising drug cost, the NHS drug spending soared to £18.2 billion in 2017/2018 and the ‘The Future of Pharmacy Aseptic Services in England’ review found that of the existing 649 installed workstations, 402 will need to be replaced. Utilising ready-to-administer bags of cytotoxic treatment can reduce waste and improve the current chemotherapy supply chains to be more agile, leaner and resilient to drug shortages thereby creating better value for the taxpayers’ money. Implementation of dose banding tables provides an opportunity to move away from bespoke products and enable the use of batch and ready-to-administer chemotherapy drugs. The primary drivers of this are cost reduction in waste and resilience in the chemotherapy supply chain. Methods: A retrospective analysis of gemcitabine and irinotecan procurement and wastage data over a 30-months period was used to compare unlicensed chemotherapy batch versus ready-to-administer doses for cost, waste and patient waiting time in the day units. Results: A total of 1802 dose units of Gemcitabine and 1355 dose units of Irinotecan were administered between January 2019 and June 2021. Ready-to-administer gemcitabine infusion was implemented in October 2019 with a gradual increase from 31% of total doses to an average of 82.5% per month. Irinotecan ready-to-administer infusion was implemented in March 2021 with a gradual increase from 21.5% to 64.3%. Patient waiting times on average shortened by 32 min post-implementation. A reduction of 63.8% and 67% in the value of gemcitabine and irinotecan wasted through the introduction of ready-to-administer products was observed. However, as the products do not cover all dose ranges, batch doses were still in use for 1300 mg and 1500 mg gemcitabine. Additionally, an average monthly saving of £1400 was observed on drug costs of ready-to-administer doses versus batch doses. Conclusion: Aseptic compounding is currently the biggest challenge facing the delivery of chemotherapy treatments and organisations within the NHS need to make the most efficient use of the limited capacity. This study shows that implementation of licensed ready-to-administer doses reduces waste through increased shelf life, reduces costs and improves the availability of doses for patients. [ABSTRACT FROM AUTHOR]